AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 187 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $305,712 | -93.8% | 12,352 | -92.9% | 0.00% | -100.0% |
| Q2 2023 | $4,927,822 | +347664.4% | 174,005 | +182.1% | 0.00% | +100.0% |
| Q1 2023 | $1,417 | +236.6% | 61,689 | +311.3% | 0.00% | – |
| Q4 2022 | $421 | -100.0% | 15,000 | -74.3% | 0.00% | -100.0% |
| Q3 2022 | $1,652,000 | -39.8% | 58,421 | -52.8% | 0.00% | -50.0% |
| Q2 2022 | $2,745,000 | +130.9% | 123,830 | +203.2% | 0.00% | +100.0% |
| Q1 2022 | $1,189,000 | -59.9% | 40,835 | -54.7% | 0.00% | -50.0% |
| Q4 2021 | $2,966,000 | +373.0% | 90,239 | +564.1% | 0.00% | – |
| Q3 2021 | $627,000 | -95.1% | 13,588 | -94.5% | 0.00% | -100.0% |
| Q1 2021 | $12,849,000 | -2.5% | 248,815 | -18.2% | 0.01% | 0.0% |
| Q4 2020 | $13,184,000 | +383.5% | 304,265 | +290.6% | 0.01% | +233.3% |
| Q3 2020 | $2,727,000 | -76.4% | 77,902 | -63.9% | 0.00% | -81.2% |
| Q2 2020 | $11,539,000 | +17.0% | 215,752 | -22.4% | 0.02% | -27.3% |
| Q1 2020 | $9,861,000 | -40.3% | 277,928 | -19.7% | 0.02% | +4.8% |
| Q4 2019 | $16,531,000 | +77.1% | 346,203 | +20.2% | 0.02% | +40.0% |
| Q3 2019 | $9,334,000 | +30.4% | 288,108 | +100.7% | 0.02% | +50.0% |
| Q2 2019 | $7,160,000 | -28.1% | 143,542 | -33.5% | 0.01% | -37.5% |
| Q4 2018 | $9,955,000 | +133.0% | 215,902 | +289.7% | 0.02% | +220.0% |
| Q3 2018 | $4,273,000 | +95.1% | 55,409 | +47.7% | 0.01% | +25.0% |
| Q1 2017 | $2,190,000 | -82.0% | 37,506 | -87.2% | 0.00% | -84.0% |
| Q4 2016 | $12,199,000 | +164.7% | 292,310 | +235.1% | 0.02% | +212.5% |
| Q3 2016 | $4,608,000 | +7.9% | 87,240 | -14.4% | 0.01% | -20.0% |
| Q2 2016 | $4,269,000 | -87.9% | 101,901 | -88.2% | 0.01% | -88.6% |
| Q1 2016 | $35,157,000 | +1206.5% | 865,939 | +1988.9% | 0.09% | +1366.7% |
| Q4 2015 | $2,691,000 | -58.9% | 41,454 | -40.2% | 0.01% | -50.0% |
| Q1 2015 | $6,541,000 | +393.7% | 69,363 | +221.1% | 0.01% | +300.0% |
| Q3 2014 | $1,325,000 | -0.5% | 21,600 | -36.5% | 0.00% | -25.0% |
| Q1 2014 | $1,331,000 | – | 34,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |